Russian eligibility criteria prescribing menopausal hormonal hormones therapy for patients with cardiovascular and metabolic diseases. Consensus document of the Russian Cardiological Society, Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists, Eurasian Association of Therapists, Association of Phlebologists of Russia
Menopausal symptoms can disrupt the life course of women at the peak of their career and family life. Currently, the most effective treatment for these manifestations is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases in itself does not exclude the possibility of prescribing MHT to relieve menopausal symptoms and improve quality of life. However, often an obstacle to the use of this type of hormonal therapy is the fear of doctors who are afraid of doing more harm to patients than good. Caution is especially important when it comes to women with underlying health conditions. Moreover, it should be recognized that there is a lack of high-quality research regarding the safety of MHT for major chronic non-infectious diseases and common comorbid conditions. The presented consensus document analyzed all currently available data obtained from clinical trials of various designs and created a set of criteria for the acceptability of prescribing MHT to women with concomitant cardiovascular and metabolic diseases. Based on the presented document, doctors of various specialties who advise women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and reasonably prescribe MHT in real practice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:69 |
|---|---|
| Enthalten in: |
Problemy endokrinologii - 69(2023), 5 vom: 12. Nov., Seite 115-136 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Shlyakhto, E V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 17.11.2023 Date Revised 29.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.14341/probl13394 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364605405 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364605405 | ||
| 003 | DE-627 | ||
| 005 | 20231226095800.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.14341/probl13394 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1215.xml |
| 035 | |a (DE-627)NLM364605405 | ||
| 035 | |a (NLM)37968959 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Shlyakhto, E V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Russian eligibility criteria prescribing menopausal hormonal hormones therapy for patients with cardiovascular and metabolic diseases. Consensus document of the Russian Cardiological Society, Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists, Eurasian Association of Therapists, Association of Phlebologists of Russia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.11.2023 | ||
| 500 | |a Date Revised 29.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Menopausal symptoms can disrupt the life course of women at the peak of their career and family life. Currently, the most effective treatment for these manifestations is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases in itself does not exclude the possibility of prescribing MHT to relieve menopausal symptoms and improve quality of life. However, often an obstacle to the use of this type of hormonal therapy is the fear of doctors who are afraid of doing more harm to patients than good. Caution is especially important when it comes to women with underlying health conditions. Moreover, it should be recognized that there is a lack of high-quality research regarding the safety of MHT for major chronic non-infectious diseases and common comorbid conditions. The presented consensus document analyzed all currently available data obtained from clinical trials of various designs and created a set of criteria for the acceptability of prescribing MHT to women with concomitant cardiovascular and metabolic diseases. Based on the presented document, doctors of various specialties who advise women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and reasonably prescribe MHT in real practice | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Hormones |2 NLM | |
| 700 | 1 | |a Sukhikh, G T |e verfasserin |4 aut | |
| 700 | 1 | |a Serov, V N |e verfasserin |4 aut | |
| 700 | 1 | |a Dedov, I I |e verfasserin |4 aut | |
| 700 | 1 | |a Arutyunov, G P |e verfasserin |4 aut | |
| 700 | 1 | |a Suchkov, I A |e verfasserin |4 aut | |
| 700 | 1 | |a Orlova, Ya A |e verfasserin |4 aut | |
| 700 | 1 | |a Andreeva, E N |e verfasserin |4 aut | |
| 700 | 1 | |a Yureneva, S V |e verfasserin |4 aut | |
| 700 | 1 | |a Yavelov, I S |e verfasserin |4 aut | |
| 700 | 1 | |a Yarmolinskaya, M I |e verfasserin |4 aut | |
| 700 | 1 | |a Villevalde, S V |e verfasserin |4 aut | |
| 700 | 1 | |a Grigoryan, O R |e verfasserin |4 aut | |
| 700 | 1 | |a Dudinskaya, E N |e verfasserin |4 aut | |
| 700 | 1 | |a Ilyukhin, E A |e verfasserin |4 aut | |
| 700 | 1 | |a Koziolova, N A |e verfasserin |4 aut | |
| 700 | 1 | |a Sergienko, I V |e verfasserin |4 aut | |
| 700 | 1 | |a Smetnik, A A |e verfasserin |4 aut | |
| 700 | 1 | |a Tapilskaya, N I |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Problemy endokrinologii |d 1967 |g 69(2023), 5 vom: 12. Nov., Seite 115-136 |w (DE-627)NLM000043842 |x 2308-1430 |7 nnns |
| 773 | 1 | 8 | |g volume:69 |g year:2023 |g number:5 |g day:12 |g month:11 |g pages:115-136 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.14341/probl13394 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 69 |j 2023 |e 5 |b 12 |c 11 |h 115-136 | ||